Targeted therapies for myeloproliferative neoplasms
Abstract The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivota...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2019-07-01
|
| Schriftenreihe: | Biomarker Research |
| Schlagworte: | |
| Online-Zugang: | http://link.springer.com/article/10.1186/s40364-019-0166-y |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|